Skip to main content
. Author manuscript; available in PMC: 2023 Jan 1.
Published in final edited form as: Neuroendocrinology. 2021 Jan 12;112(1):34–42. doi: 10.1159/000514339

Table 1:

Demographics and clinical characteristics of all 243 patients treated with FAS

Characteristic N=243
N (%)
Age, years
Median 56
Interquartile range 47–63
Sex
 Male 137 (56)
 Female 106 (44)
Tumor type
 Nonfunctioning 218 (90)
 Functioning 25 (10)
Genetic syndrome
 Sporadic 231 (95)
 Multiple endocrine neoplasia type 1 12 (5)
Tumor status
 Locally advanced 20 (8)
 Metastatic 223 (92)
FAS line of therapy
 First 208 (86)
 Second or greater 35 (14)
Resection of the primary tumor
 No 191 (79)
 Yes 52 (21)
First post-FAS scan result, % (95% CI)
 Complete or partial response 41 % (95% CI: 36–48%)